User:Natalie Van Ochten/Sandbox 1

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 3: Line 3:
=Introduction=
=Introduction=
-
Dimethylarginine Dimethyaminohydrolase (commonly known as DDAH) is a member of the hydrolase family of enzymes which use water to break down molecules <ref name="palm"[doi:10.1152/ajpheart.00998.2007] </ref>. Specifically, DDAH is a nitric oxide synthase (NOS) regulator. Its metabolizes free arginine derivatives, namely NѠ,NѠ-dimethyl-L-arginine (ADMA) and NѠ-methyl-L-arginine (MMA) which competitively inhibit NOS <ref name="tran"[doi:10.1016/S1567-5688(03)00032-1]</ref>. DDAH converts MMA and ADMA to L-citrulline and monoamine or dimethylamine <ref name="frey"[doi:10.1016/j.str.2006.03.006]</ref>. DDAH is expressed in the cytosol of cells in humans, mice, rates, sheep, cattle, and bacteria <ref name="palm" />. DDAH activity has been localized mainly to the brain, kidney, pancreas, and liver in these organisms. If DDAH is overexpressed, NOS can be activated <ref name="frey" />. ADMA and MMA can inhibit the synthesis of NO by competitively inhibiting all three kinds of NOS (endothelial, neuronal, and inducible) <ref name="frey" />. Underexpression or inhibition of DDAH decreases NOS activity and NO levels will decrease. Because of nitric oxide’s (NO) role in signaling and defense, NO levels in an organism must be regulated to reduce damage to cells <ref name="janssen"[doi:10.1002/path.4127/full]</ref>. NO is made by NOS creating L-citrulline from L-arginine <ref name="frey" />. In humans, many diseases can come from improper control of NO levels including diabetes mellitus and hypertension. Current research has identified several inhibitors of DDAH which could be important in fighting diseases involving irregular NO levels <ref name="frey" />.
+
Dimethylarginine Dimethyaminohydrolase (commonly known as DDAH) is a member of the hydrolase family of enzymes which use water to break down molecules <ref name="palm"[http://www.sciencedirect.com/science/article/pii/S0969212606001717] </ref>. Specifically, DDAH is a nitric oxide synthase (NOS) regulator. Its metabolizes free arginine derivatives, namely NѠ,NѠ-dimethyl-L-arginine (ADMA) and NѠ-methyl-L-arginine (MMA) which competitively inhibit NOS <ref name="tran"[doi:10.1016/S1567-5688(03)00032-1]</ref>. DDAH converts MMA and ADMA to L-citrulline and monoamine or dimethylamine <ref name="frey"[doi:10.1016/j.str.2006.03.006]</ref>. DDAH is expressed in the cytosol of cells in humans, mice, rates, sheep, cattle, and bacteria <ref name="palm" />. DDAH activity has been localized mainly to the brain, kidney, pancreas, and liver in these organisms. If DDAH is overexpressed, NOS can be activated <ref name="frey" />. ADMA and MMA can inhibit the synthesis of NO by competitively inhibiting all three kinds of NOS (endothelial, neuronal, and inducible) <ref name="frey" />. Underexpression or inhibition of DDAH decreases NOS activity and NO levels will decrease. Because of nitric oxide’s (NO) role in signaling and defense, NO levels in an organism must be regulated to reduce damage to cells <ref name="janssen"[doi:10.1002/path.4127/full]</ref>. NO is made by NOS creating L-citrulline from L-arginine <ref name="frey" />. In humans, many diseases can come from improper control of NO levels including diabetes mellitus and hypertension. Current research has identified several inhibitors of DDAH which could be important in fighting diseases involving irregular NO levels <ref name="frey" />.
=General Structure=
=General Structure=

Revision as of 13:13, 28 March 2017

Dimethylarginine Dimethylaminohydrolase

Dimethylarginine Dimethylaminohydrolase with Zn2+ bound at pH 6.3

Drag the structure with the mouse to rotate

References

Tran CTL, Leiper JM, Vallance P. The DDAH/ADMA/NOS pathway. Atherosclerosis Supplements. 2003 Dec;4(4):33-40. PMID:14664901 doi:10.1016/S1567-5688(03)00032-1

Frey D, Braun O, Briand C, Vasak M, Grutter MG. Structure of the mammalian NOS regulator dimethylarginine dimethylaminohydrolase: a basis for the design of specific inhibitors. Structure. 2006 May;14(5):901-911. PMID:16698551 doi:10.1016/j.str.2006.03.006

Janssen W, Pullamsetti SS, Cooke J, Weissmann N, Guenther A, Schermuly RT. The role of dimethylarginine dimethylaminohydrolase (DDAH) in pulmonary fibrosis. The Journal of Pathology. 2012 Dec 12;229(2):242-249. Epub 2013 Jan. PMID: 23097221 doi:10.1002/path.4127/full

Palm F, Onozato ML, Luo Z, Wilcox CS. Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. American Journal of Physiology. 2007 Dec 1;293(6):3227-3245. PMID:17933965 doi:10.1152/ajpheart.00998.2007

Rasheed M, Richter C, Chisty LT, Kirkpatrick J, Blackledge M, Webb MR, Driscoll PC. Ligand-dependent dynamics of the active site lid in bacterial Dimethyarginine Dimethylaminohydrolase. Biochemistry. 2014 Feb 18;53:1092-1104. PMCID:PMC3945819 doi:10.1021/bi4015924

Stone EM, Costello AL, Tierney DL, Fast W. Substrate-assisted cysteine deprotonation in the mechanism of Dimethylargininase (DDAH) from Pseudomonas aeruginosa. Biochemistry. 2006 May 2;45(17):5618-5630. PMID:16634643 doi:10.1021/bi052595m

Proteopedia Page Contributors and Editors (what is this?)

Natalie Van Ochten

Personal tools